Review of child hip surgery cases won't begin until January, HSE confirms
It comes after a clinical audit of surgeries for dysplasia of the hips in children found that a lower threshold for operations was used at CHI Temple Street hospital and the National Orthopaedic Hospital Cappagh (NOHC) than the threshold used at CHI Crumlin.
Advertisement
The review discovered that in the period 2021 to 2023, almost 80 per cent of children operated on at the NOHC, and 60 per cent of those at Temple Street, did not meet the threshold for surgery.
In a statement, the HSE said an expert review is being commissioned and the independent panel will be convened to review patient files 'to determine, in so far as possible, the appropriateness of the original decision to operate in individual cases'.
It said this would be based on the 'appropriate radiological indices and clinical history' of the cases.
An international call for experts to apply for the panel closed on Friday and saw submissions from Ireland, the UK, the US, Canada, Asia, and other parts of Europe.
Advertisement
The HSE said these submissions will be subject to a shortlisting and recruitment process prior to the formal announcement of the panel, which is expected to convene in September.
It is also negotiating terms and conditions for an independent international expert to chair the panel who has already been identified, adding that their name will be published 'in due course'.
The HSE added: 'It is expected that the review of individual cases will commence in January. This timeline reflects the complexity of the work involved and the need to ensure a rigorous and comprehensive approach.
'This is a highly complex piece of work that requires sufficient time for planning and preparation. As such the following steps are in progress.'
Advertisement
The HSE said it had 'engaged meaningfully with patient advocates' and a workshop is being scheduled to progress terms of reference for the review.
The Hip Dysplasia Advocacy Group, acting for children who may have undergone unnecessary surgeries, met CHI and HSE officials last Thursday.
It said it was told the HSE is aiming for a six-month timeframe for the process.
In a statement, it said: 'There has yet to be any correspondence surrounding the retrospective review from the HSE to the families of the children who are potentially affected.
Advertisement
'We, the advocacy group, relayed this information to the families immediately post our meeting. Representatives from the Hip Dysplasia Advocacy Group said that this is unacceptable.
'There needs to be full transparency between the HSE and the families regarding these reviews, everyone is left completely in the dark.'
Ireland
Tánaiste agrees to meet parents of boy who died af...
Read More
It added that the HSE is yet to confirm the criteria it will use to assess the children's need for surgery.
'A member from the HSE has suggested it will be determined by the expert panel when they are appointed.
Advertisement
'We have asked for the HSE to issue an update to all families involved as the lack of correspondence to parents is unacceptable. They have been left in limbo.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
5 hours ago
- The Independent
Investigation launched as vulnerable animals wash up dead
At least 32 turtles, including 25 vulnerable green turtles, have been found washed up dead on shores across the Port Stephens Council area in New South Wales, Australia. Some of the deceased turtles exhibited unusual symptoms, such as bleeding around the eyes, which conservationists describe as very worrying. Multiple agencies, including New South Wales's National Parks and Wildlife Services and Taronga Zoo, are conducting a thorough investigation, collecting samples for testing, with autopsy data expected in several weeks. Sea Shelter, a marine rescue group, recorded 25 green turtle deaths in the past month in Port Stephens, with one founder noting an increase in deaths after recent flooding in the area. The public has been urged to report any sick or injured sea turtles to the National Parks and Wildlife Services or Irukandji Shark and Ray Encounters.
Reuters
5 hours ago
- Reuters
Rocket Pharma's shares soar after US FDA lets gene therapy trial resume
Aug 20 (Reuters) - The U.S. health regulator has allowed a study of Rocket Pharmaceuticals' (RCKT.O), opens new tab gene therapy to resume, less than three months after halting it following a patient's death. The drugmaker's shares soared over 30% in morning trading on Wednesday. Rocket's mid-stage trial, testing its experimental therapy, RP-A501, for a genetic disorder called Danon disease, was halted in May by the Food and Drug Administration after a patient died from a rare complication. The company said on Wednesday that the FDA has lifted its clinical hold on the trial, to be resumed with a revised pre-treatment regime and a lower dose of the gene therapy. Rocket said it will discontinue prophylactic use of drugs that inhibit the C3 protein, which is part of the immune system, as part of the pre-treatment regime. The patient who died in the May trial was one of two who were administered the C3 inhibitors. The patient had suffered from capillary leak syndrome, which can cause organ failure. In the new trial, three patients, at least four weeks apart, are expected to receive a lower dose of its therapy. Rocket said the adjusted dose was proposed based on data from an early-stage study, which showed a better safety profile. Danon disease, which affects males more severely than females, causes heart muscle damage and progressive muscle weakness. Fewer than 1,000 people in the United States are currently known to have the condition, according to National Institutes of Health.
Daily Mail
7 hours ago
- Daily Mail
Doctors pinpoint subtle sign of deadly neurological disease that kills thousands - and it appears 15 YEARS before diagnosis
Multiple sclerosis (MS) could be diagnosed over a decade earlier following intriguing new research which found signs of the condition such as vision problems, anxiety and fatigue develop 15 years before more well-known symptoms. More than 150,000 people in the UK have MS, a debilitating autoimmune disease that can cause problems with sight, writing, speaking and walking as the nerves in the brain and spinal cord become permanently damaged. People usually start to experience symptoms between the ages of 20 and 40 years. But researchers now believe an increase in the number of GP and hospital visits linked to these issues could help flag people who are in the early stages of the disease. A groundbreaking new study analysed the health records of over 2,000 MS patients, and tracked healthcare visits 25 years before the onset of typical symptoms. The researches, from British Columbia, Canada, found a steady increase in the number of GP visits as early as 15 years before neurological symptoms took hold. This included an increase in appointments related to extreme fatigue, pain, dizziness, anxiety and depression. Whilst experts say this does not mean doctors will now be able to pinpoint if someone will go on to develop MS 15 years before the onset of neurological symptoms, the results may help doctors catch the condition earlier. Dr Catherine Godbold, senior research communications manager at the MS society, who was not involved in the study, told the Daily Mail: 'We know that in the years leading up to an MS diagnosis, people often see their GP more and have more recorded health issues. 'Now this study has shown it may begin even earlier than we thought. 'We need more research to know which specific combination of symptoms are the most reliable early cues but the results provide valuable information to help us better understand the very early period in MS.' Researchers say understanding what's happening in the brain and spinal cord during the prodromal stage could help diagnose the condition earlier, allowing patients to start treatment sooner and slow down the progression of the disease. Previously, other researchers had found symptoms that appear five years before diagnosis, such as constipation, recurrent urinary tract infections (UTIs) and sexual problems. However, because of the unpredictability of symptoms it can often take patients years to receive a diagnosis. Whilst the precise causes of MS are still unknown, it is thought that the condition is caused by an abnormal immune response which triggers inflammation and damages the central nervous system. Specifically, it targets the myelin sheath—the protective layer of protein and fatty acids which protects the nerves that carry signals from the brain. While MS does not directly kill, at advanced stages, it can cause weakness in the chest muscles, leading to difficulty breathing and swallowing—which can have life-threatening complications. Those in the late stages of the illness are also extremely vulnerable to potentially deadly infections. The breakthrough comes following a concerning rise in cases, with around 150,000 people living with the debilitating condition in the UK. This is up from around 130,000 in 2019, according to recent research by the MS Society. There is currently no cure but treatments can slow the progression of the disease. Treatment plans vary depending on the type of MS a patient has: relapsing remitting, secondary progressive or primary progressive MS. Relapse and remitting MS involves flare-ups of symptoms where they get worse (relapse) and get better (remission). Over time it often develops into secondary progressive MS, when symptoms are there all the time, and get slowly worse. In the less common case of primary progressive MS, symptoms slowly getting worse over time without periods of them going away or getting better. Treatments may include several types of medication such as steroids, disease-modifying therapies, muscle relaxants, and those to treat pain and other symptoms. Other types of support include advice on fatigue, physiotherapy, mobility equipment, talking therapies, and cognitive rehabilitation.
